Polidocanol
- Generic Name
- Polidocanol
- Brand Names
- Asclera, Varithena
- Drug Type
- Small Molecule
- Chemical Formula
- C30H62O10
- CAS Number
- 9002-92-0
- Unique Ingredient Identifier
- 0AWH8BFG9A
- Background
Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena. The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.
- Indication
Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.
- Associated Conditions
- Pain caused by Teething, Incompetent accessory saphenous veins, Incompetent great saphenous veins, Superficial venous incompetence, Uncomplicated veins 1 to 3 mm in diameter reticular veins, Uncomplicated veins <1 mm in diameter Spider Veins, Varicosities of the great saphenous vein
Assessing the Efficacy of Repeat, Monthly Treatments of Cutaneous Neurofibromas (cNFs)
- Conditions
- Neurofibromatosis 1Neurofibromas, Cutaneous
- Interventions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06300502
- Locations
- 🇺🇸
Wellman Center for Photomedicine, Boston, Massachusetts, United States
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
- Conditions
- Neurofibromatosis 1
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06132165
- Locations
- 🇺🇸
Wellman Center for Photomedicine, Boston, Massachusetts, United States
Dosing and Tolerability of Deoxycholic Acid Vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06120036
- Locations
- 🇺🇸
Wellman Center for Photomedicine, Boston, Massachusetts, United States
Comparative Study of Polidocanol and Absolute Alcohol for Percutaneous us Guided Treatment of Benign Thyroid Cyst
- Conditions
- Thyroid LumpThyroid CystBenign Thyroid Nodule
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 30
- Registration Number
- NCT05798936
Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)
- Conditions
- Varicose Veins
- Interventions
- Device: FDA-approved Endothermal Ablation (ETA) systems
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 43
- Registration Number
- NCT05312970
- Locations
- 🇺🇸
Vascular Care Connecticut, Darien, Connecticut, United States
🇺🇸Cardiovascular Institute of the South, Houma, Louisiana, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Polidocanol Foam VS Artery Ligation in Hemorrhoidal Disease
- Conditions
- Hemorrhoids
- Interventions
- Procedure: Doppler-guided hemorrhoidal artery ligation
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Universidade do Porto
- Target Recruit Count
- 45
- Registration Number
- NCT04675177
- Locations
- 🇵🇹
Centro Hospitalar Universitário do Porto, Porto, Portugal
Polidocanol Foam Versus Rubber Band Ligation in the Treatment of Hemorrhoidal Disease
- Conditions
- Hemorrhoids, Internal
- Interventions
- Device: Rubber band ligation
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Universidade do Porto
- Target Recruit Count
- 120
- Registration Number
- NCT04091763
- Locations
- 🇵🇹
Centro Hospitalar Universitário do Porto, Porto, Portugal
Efficacy and Safety of Polidocanol Foam 3% in the Treatment of II Degree Hemorrhoidal Disease
- Conditions
- Second-degree Hemorrhoids
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Societa Italiana di Chirurgia ColoRettale
- Target Recruit Count
- 183
- Registration Number
- NCT03791775
- Locations
- 🇮🇹
University of Catanzaro, Catanzaro, Italy
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
- Conditions
- In-Transit Metastasis of Cutaneous MelanomaMelanoma
- Interventions
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Melanoma Institute Australia
- Registration Number
- NCT03754140
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
- Conditions
- Venous Leg Ulcer
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 76
- Registration Number
- NCT03257254
- Locations
- 🇺🇸
Pines Clinical Research, Aventura, Florida, United States
🇨🇦Oakville Vascular, Oakville, Ontario, Canada
🇺🇸OhioHealth Research, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.